Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SB225002 is a potent and selective CXCR2 antagonist inhibiting interleukin IL-8 binding to CXCR2.
説明 | SB225002 is a potent and selective CXCR2 antagonist inhibiting interleukin IL-8 binding to CXCR2. |
ターゲット&IC50 | CXCR2:22 nM |
In vitro | SB225002 demonstrates prolonged analgesic effects and reduces TNBS-induced colitis in mouse models. In rabbits, SB225002 selectively inhibits the margination of neutrophils induced by IL-8. Moreover, at a dosage of 1 mg/kg i.p., SB225002 suppresses the growth of subcutaneously transplanted tumors in a mouse model of intrahepatic cholangiocarcinoma. |
In vivo | SB225002 demonstrates antitumor activity as a microtubule inhibitor. It significantly reduces the levels of phosphorylated ERK1/2 and decreases the proliferation of WHCO1 cells. In vitro, SB225002 inhibits calcium mobilization stimulated by GROα and effectively suppresses the chemotaxis of human and rabbit neutrophils induced by IL-8 and GROα. |
キナーゼ試験 | Radioligand Binding Experiments: Assays are performed in 96-well microtiter plates where the reaction mixture contains 1.0 μg/ml membrane protein in 20 mM Bis-Tris-propane, pH 8.0, with 1.2 mM MgSO4, 0.1 mM EDTA, 25 mM NaCl, and 0.03% CHAPS and SB 225002 (10 mM stock in Me2SO) added at the indicated concentrations, the final Me2SO concentration is <1% under standard binding conditions. Binding is initiated by addition of 0.25 nM 125I-IL-8 (2,200 Ci/mmol). After 1-h incubation at room temperature the plate is harvested using a Tomtec 96-well harvester onto a glass fiber filtermat blocked with 1% polyethyleneimine, 0.5% BSA and washed three times with 25 mM NaCl, 10 mM Tris·HCl, 1 mM MgSO4, 0.5 mM EDTA, 0.03% CHAPS, pH 7.4. The filter is dried, sealed in a sample bag containing 10 ml of Wallac 205 Betaplate liquid scintillation fluid, and counted with a Wallac 1205 Betaplate liquid scintillation counter. |
細胞研究 | Three esophageal squamous cell carcinoma cell lines WHCO1, WHCO5, and WHCO6 originally established from surgical biopsies of primary esophageal squamous cell carcinomas are cultured in DMEM containing 10% FCS at 37°C in a humidified atmosphere of 5% CO2. MTT assays are carried out using the Cell Proliferation kit I. Briefly, 1.5 × 103 cells are plated in 96-well plates in a final volume of 180 μL DMEM per well. SB 225002 (antagonist of CXCR2, 400 nM) is added to cells and 0.001% DMSO (solvent) is added as a control. After the indicated incubation period, 18 μL of the MTT labeling reagent (final concentration 0.5 mg/mL) is added to each well and incubated for 4 hours in a humidified atmosphere. One hundred eighty microliters of the solubilization solution are added to each well and the plates were left overnight at 37°C. The spectrophotometric absorbance of samples is measured at 595 nm using a microtiter plate reader.(Only for Reference) |
分子量 | 352.14 |
分子式 | C13H10BrN3O4 |
CAS No. | 182498-32-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 65 mg/mL (184.6 mM)
Ethanol: 3 mg/mL (8.51 mM), Heating is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
SB225002 182498-32-4 Autophagy GPCR/G Protein Immunology/Inflammation CXCR SB-225002 CXC chemokine receptors Inhibitor inhibit SB 225002 inhibitor